Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 6/20 | 0.51 |
| ▸ | GNRHR | P30968 | 13/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248548 | 0.79 | HTR1A (0.51) | HTR6GNRHRDRD2DRD4DRD3 | |
| SCHEMBL3258402 | 0.71 | MGAM (0.45) | — | |
| SCHEMBL2163311 | 0.70 | MAPT (0.40) | HTR6 | |
| SCHEMBL9697197 | 0.70 | PSMD14 (0.34) | HTR6 | |
| SCHEMBL4633990 | 0.69 | CHEK1 (0.50) | HTR6 | |
| SCHEMBL10634828 | 0.69 | GRIN2B (0.50) | — | |
| SCHEMBL4899723 | 0.67 | PARP1 (0.54) | HTR6GNRHR | |
| SCHEMBL1628968 | 0.66 | KDM4E (0.36) | — | |
| SCHEMBL9232152 | 0.66 | KDM4E (0.38) | — | |
| SCHEMBL5182911 | 0.65 | CNR2 (0.45) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2285784-B1 | 2-METHYL-1-(PHENYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLE AS 5-HYDROXYTRYPTAMINE-6 LIGAND | WYETH LLC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-8063053-B2 | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1H-benzimidazoles as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2285784-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth LLC (US) | 2011-02-23 | — | — | EP | disclosed |
| WO-2010056644-A1 | 1- (ARYLSULFONYL) -4- (PI PERAZIN-I -YL) -IH-BENZ IMIDAZOLES AS δ-HYDROXYTRYPTAMINE- 6 LIGANDS | WYETH LLC (US) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120779-A1 | 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | HTR6, TPH1, HTR4 | HTR6 1/4885GNRHR 2571/4885DRD2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.